公开(公告)号：WO2017096165A1

公开(公告)日：2017-06-08

申请号：PCT/US2016/064619

申请日：2016-12-02

Applicant: AGIOS PHARMACEUTICALS, INC.

Inventor： MARJON, Katya ,  CHOE, Sung Eun

IPC: A61K31/015 ,  A61K45/00 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/015 ,  A61K31/505 ,  A61K45/00

Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a MAT2A inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a MAT2A inhibitor, comprising assessing whether the tumor cell is absent an MTAP gene whereby cells that are MTAP null are sensitive to inhibition by MAT2A inhibitors.

Abstract translation: 本发明提供了用于预测用MAT2A抑制剂治疗癌症患者的有效性的诊断和预后方法。 提供了用于预测肿瘤细胞生长对MAT2A抑制剂抑制的敏感性的方法，包括评估肿瘤细胞是否不存在MTAP基因，由此MTAP无效的细胞对MAT2A抑制剂的抑制敏感。

公开(公告)号：WO2019164794A1

公开(公告)日：2019-08-29

申请号：PCT/US2019/018472

申请日：2019-02-19

Applicant: AGIOS PHARMACEUTICALS, INC.

Inventor： ULANET, Danielle ,  CHOE, Sung Eun

IPC: A61K31/4192

Abstract: The present invention provides methods for treating cancer in a subject with a trisubstituted benzotriazole derivative with the formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R 1 , R 2 and R 3 are as defined herein.